Adipokines in Multiple Sclerosis Patients with and without Optic Neuritis as the First Clinical Presentation

Basit Öğe Kaydı
dc.contributor.authorDuzel, Berna
dc.contributor.authorTamam, Yusuf
dc.contributor.authorCoban, Arzu
dc.contributor.authorTuzun, Erdem
dc.date.accessioned2024-04-24T16:24:38Z
dc.date.available2024-04-24T16:24:38Z
dc.date.issued2019
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: Adipocytokines have been implied to be involved in multiple sclerosis (MS) pathogenesis. MS patients whose first clinical episode is optic neuritis (ON) have been reported to display a milder disease course. In this study, we aimed to show whether this milder disease course is related to reduced adipokine production. Methods: A total of 55 (24 with ON as the first clinical episode) relapsing-remitting MS (RRMS) patients and 40 healthy individuals were recruited. Concentrations of adipokines were measured in sera by ELISA. Results: The levels of adiponectin, leptin, resistin, monocyte chemoattractant protein-1 (MCP-1) and IL-8 were significantly higher in RRMS patients compared with healthy controls. RRMS cases starting with ON had lower expanded disability status scale scores. Serum adiponectin, leptin, resistin and MCP-1 levels were significantly lower in MS patients, whose first clinical episode was ON. Conclusions: MS patients with ON as the first manifestation display both lower disability scores and reduced serum adipokine levels implying that adipocytokine production is associated with MS progression. Exact mechanisms of this association in MS patients with first episode ON need to be further studied.en_US
dc.description.sponsorshipScientific Research Projects Coordination Unit of Dicle University [TIP.16.003]en_US
dc.description.sponsorshipThis work was supported by Scientific Research Projects Coordination Unit of Dicle University (project number: TIP.16.003)en_US
dc.identifier.doi10.1080/08820139.2018.1528270
dc.identifier.endpage197en_US
dc.identifier.issn0882-0139
dc.identifier.issn1532-4311
dc.identifier.issue2en_US
dc.identifier.pmid30321074
dc.identifier.scopus2-s2.0-85055027941
dc.identifier.scopusqualityQ3
dc.identifier.startpage190en_US
dc.identifier.urihttps://doi.org/10.1080/08820139.2018.1528270
dc.identifier.urihttps://hdl.handle.net/11468/16795
dc.identifier.volume48en_US
dc.identifier.wosWOS:000457411600008
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.ispartofImmunological Investigations
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdipokineen_US
dc.subjectDisabilityen_US
dc.subjectFirst Clinical Episodeen_US
dc.subjectMultiple Sclerosisen_US
dc.subjectOptic Neuritisen_US
dc.titleAdipokines in Multiple Sclerosis Patients with and without Optic Neuritis as the First Clinical Presentationen_US
dc.titleAdipokines in Multiple Sclerosis Patients with and without Optic Neuritis as the First Clinical Presentation
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu